The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Open accessAbstract
BACKGROUND: Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefit from thromboprophylaxis. METHODS: We conducted a randomized, placebo-controlled, double-blind clinical trial assessing the efficacy and safety of apixaban (2.5 mg twice daily) for thromboprophylaxis in ambulatory patients with cancer who were at intermediate-to-high risk for venous thromboembolism (Khorana score, ≥2) and were initiating chemotherapy. The primary efficacy outcome was objectively documented venous thromboembolism over a follow-up period of 180 days. The main safety outcome was a major bleeding episode. RESULTS: Of the 574 patients who underwent randomization, 563 were included in the modified intention-to-treat analysis. Venous thromboembolism occurred in 12 of 288 patients (4.2%) in the apixaban group and in 28 of 275 patients (10.2%) in the placebo group (hazard ratio, 0.41; 95% confidence interval [CI], 0.26 to 0.65; P<0.001). In the modified intention-to-treat analysis, major bleeding occurred in 10 patients (3.5%) in the apixaban group and in 5 patients (1.8%) in the placebo group (hazard ratio, 2.00; 95% CI, 1.01 to 3.95; P = 0.046). During the treatment period, major bleeding occurred in 6 patients (2.1%) in the apixaban group and in 3 patients (1.1%) in the placebo group (hazard ratio, 1.89; 95% CI, 0.39 to 9.24). CONCLUSIONS: Apixaban therapy resulted in a significantly lower rate of venous thromboembolism than did placebo among intermediate-to-high-risk ambulatory patients with cancer who were starting chemotherapy. The rate of major bleeding episodes was higher with apixaban than with placebo. (Funded by the Canadian Institutes of Health Research and Bristol-Myers Squibb-Pfizer Alliance; AVERT ClinicalTrials.gov number, NCT02048865.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Prandoni, P., Lensing, A. W. A., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0108 · Cited by 1,863
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633
Self-citationPrognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Self-citationYoung, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,348
Prediction of venous thromboembolism in cancer patients
Ay, C., Dunkler, D., Marosi, C., Chiriac, A.-L., Vormittag, R., Simanek, R., Quehenberger, P., Zielinski, C., & Pabinger, I. (2010) · Blood · doi:10.1182/blood-2010-02-270116 · Cited by 772
BLOM, J. W., VANDERSCHOOT, J. P. M., OOSTINDIËR, M. J., OSANTO, S., VAN DER MEER, F. J. M., & ROSENDAAL, F. R. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01804.x · Cited by 692
Agnelli, G., Gussoni, G., Bianchini, C., Verso, M., Mandalà, M., Cavanna, L., Barni, S., Labianca, R., Buzzi, F., Scambia, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70232-3 · Cited by 598
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Agnelli, G., George, D. J., Kakkar, A. K., Fisher, W., Lassen, M. R., Mismetti, P., Mouret, P., Chaudhari, U., Lawson, F., & Turpie, A. G. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108898 · Cited by 531
Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis
Kim, H. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1210 · Cited by 507
Outcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer
Elting, L. S., Escalante, C. P., Cooksley, C., Avritscher, E. B. C., Kurtin, D., Hamblin, L., Khosla, S. G., & Rivera, E. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.15.1653 · Cited by 269
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Di Nisio, M., Porreca, E., Ferrante, N., Otten, H.-M., Cuccurullo, F., & Rutjes, A. W. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008500.pub2 · Cited by 264
van Es, N., Di Nisio, M., Cesarman, G., Kleinjan, A., Otten, H.-M., Mahé, I., Wilts, I. T., Twint, D. C., Porreca, E., Arrieta, O., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.169060 · Cited by 231
LEVINE, M. N., GU, C., LIEBMAN, H. A., ESCALANTE, C. P., SOLYMOSS, S., DEITCHMAN, D., RAMIREZ, L., & JULIAN, J. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04693.x · Cited by 190
Lustig, D. B., Rodriguez, R. A., & Wells, P. S. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.08.002 · Cited by 49
Self-citationEerenberg, E. S., Cohen, A. T., Middeldorp, S., Raskob, G. E., Buller, H. R., Bleker, S. M., & Brekelmans, M. P. A. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0946 · Cited by 47
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Self-citationNelson, G., Bakkum-Gamez, J., Kalogera, E., Glaser, G., Altman, A., Meyer, L. A., Taylor, J. S., Iniesta, M., Lasala, J., Mena, G., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000356 · Cited by 758
Khan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32658-1 · Cited by 753
Self-citationVenous thromboembolism in cancer patients: a population-based cohort study
Mulder, F. I., Horváth-Puhó, E., van Es, N., van Laarhoven, H. W. M., Pedersen, L., Moik, F., Ay, C., Büller, H. R., & Sørensen, H. T. (2021) · Blood · doi:10.1182/blood.2020007338 · Cited by 723
Metadata
- Authors
- Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., Trinkaus, M., Tomiak, A., Lee, A. Y. Y., Gross, P. L., Lazo-Langner, A., El-Maraghi, R., Goss, G., Le Gal, G., Stewart, D., Ramsay, T., Rodger, M., Witham, D., & Wells, P. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 711-719
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2902078827
- Cited by
- 852
- References
- 20
- FWCI
- 85.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.